atrasentan hydrochloride
Small moleculeapproved
Approved
Apr 2, 2025
Clinical trial activity
20 trials · 18 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
18
Phase 3
8
Phase 4
0
Earliest trial started May 1, 2001 (NCT00036543)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2/Phase 3
- Brain Neoplasms · Phase 1
- Diabetes Mellitus · Phase 2
- Diabetic Nephropathies · Phase 3
- Endothelial Cells · Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Glomerulosclerosis, Focal Segmental · Phase 2
- Hamartoma · Phase 2
- Kidney Diseases · Phase 2
- Kidney Neoplasms · Phase 2
- Neoplasms · Phase 3
- Nephritis, Hereditary · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 3
- Renal Insufficiency, Chronic · Phase 2
Mechanism of action
- Endothelin receptor ET-AANTAGONIST
EDNRA antagonist
Approval history
- approvedApr 2, 2025
Chemistry & pharmacology
Loading structure…
SMILES
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1- Mol. weight
- 510.63 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL9194 ↗
- ChEMBLCHEMBL2106068 ↗
Also known as
- (11c)abt-627
- 2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid
- a 127722
- a-127722
- a-127722
- a-127722
- a-127722.5
- a 147627
- a-147627
- a-147627.1
- a-147627.1
- abbot-147627
- abbot-147627
- abt 627
- abt-627
- abt-627
- abt-627
- atrasentan
- atrasentan
- atrasentan
- atrasentan
- atrasentan
- atrasentan
- atrasentan hcl
- atrasentan hcl
- atrasentan hcl
- atrasentan hydrochloride
- atrasentan hydrochloride
- atrasentan hydrochloride
- atrasentan hydrochloride
- xinlay
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05834738 | Phase 2 | Jul 20, 2023 | Chinook Therapeutics, Novartis |
| NCT04573920 | Phase 2 | Feb 1, 2021 | Chinook Therapeutics, University of California, San Francisco |
| NCT04573478 | Phase 3 | Dec 1, 2020 | Chinook Therapeutics, University of California, San Francisco |
| NCT02118714 | Phase 2 | Apr 6, 2015 | AbbVie |
| NCT01858532 | Phase 3 | May 17, 2013 | AbbVie |
| NCT01399580 | Phase 2 | Aug 1, 2011 | AbbVie |
| NCT01424319 | Phase 2 | Aug 1, 2011 | Abbott, AbbVie |
| NCT01356849 | Phase 2 | Apr 1, 2011 | AbbVie |
| NCT00920764 | Phase 2 | Jun 1, 2009 | AbbVie |
| NCT00134056 | Phase 3 | Aug 1, 2006 | Department of Veteran Affairs, National Cancer Institute (NCI), Southwest Oncology Group, University of California, Davis, University of Michigan, University of Southern California |
| NCT00653328 | Phase 2 | May 1, 2003 | National Cancer Institute (NCI), Vanderbilt University |
| NCT00039429 | Phase 2 | May 1, 2003 | Eastern Cooperative Oncology Group, Johns Hopkins University, National Cancer Institute (NCI) |
| NCT00046943 | Phase 3 | Sep 1, 2002 | Abbott |
| NCT00017264 | Phase 1 | Jun 1, 2002 | Emory University, National Cancer Institute (NCI) |
| NCT00038662 | Phase 2 | May 1, 2002 | Abbott |
| NCT00181558 | Phase 2 | Dec 1, 2001 | Abbott, Harvard University |
| NCT00127478 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2001 | Abbott |
| NCT00271492 | Phase 3 | Jul 1, 2001 | Mayo Clinic, National Institutes of Health (NIH) |
| NCT00036556 | Phase 3 | Jun 1, 2001 | Abbott |
| NCT00036543 | Phase 3 | May 1, 2001 | Abbott |
Showing 20 of 20 trials
Page 1 / 1
Organizations
Research & Development (18)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 7 | 5 | 2 | 2001 |
| AbbVie | For profit | 6 | 6 | 2 | 2009 |
| National Cancer Institute (NCI) | Government | 4 | 1 | 3 | 2002 |
| Chinook Therapeutics | For profit | 3 | 3 | 2 | 2020 |
| University of California, San Francisco | Academic/Hospital | 2 | 0 | 2 | 2020 |
| Department of Veteran Affairs | Government | 1 | 0 | 1 | 2006 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| Emory University | Academic/Hospital | 1 | 0 | 1 | 2002 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2001 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2001 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2001 |
| Novartis | For profit | 1 | 0 | 1 | 2023 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2006 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Southern California | Academic/Hospital | 1 | 0 | 1 | 2006 |
| Vanderbilt University | Academic/Hospital | 1 | 1 | 1 | 2003 |
18 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Novartis | For profit | MKTG | Apr 2, 2025 |